Health Care • Biotechnology: Pharmaceutical Preparations
$0.37 ▼ -0.01
(-3.21%)
MKT CAP: $20.4M • VOL: 814.1K
52W L $0 52W H $8
ROARABLE / RQD
D- • 43/100
PIOTROSKI
3 / 9
ACTU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.5M | -$25.2M | -$25.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$22.2M | -$27.3M | -$24.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$19.2M | -$21.8M | -$21.6M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$19.2M | -$21.8M | -$21.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $13.2M | $8.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.9M | $104.2K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACTU.